Idorsia Ltd (IDIA) - Net Assets
Based on the latest financial reports, Idorsia Ltd (IDIA) has net assets worth CHF-1.18 Billion CHF (≈ $-1.49 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF480.46 Million ≈ $607.43 Million USD) and total liabilities (CHF1.66 Billion ≈ $2.09 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IDIA PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF-1.18 Billion |
| % of Total Assets | -244.88% |
| Annual Growth Rate | N/A |
| 5-Year Change | -1191.29% |
| 10-Year Change | N/A |
| Growth Volatility | 305.31 |
Idorsia Ltd - Net Assets Trend (2016–2025)
This chart illustrates how Idorsia Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see IDIA market cap overview.
Annual Net Assets for Idorsia Ltd (2016–2025)
The table below shows the annual net assets of Idorsia Ltd from 2016 to 2025. Also explore Idorsia Ltd net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CHF-1.14 Billion ≈ $-1.44 Billion |
+6.19% |
| 2024-12-31 | CHF-1.21 Billion ≈ $-1.53 Billion |
-25.13% |
| 2023-12-31 | CHF-968.72 Million ≈ $-1.22 Billion |
-46.56% |
| 2022-12-31 | CHF-660.96 Million ≈ $-835.63 Million |
-734.29% |
| 2021-12-31 | CHF104.20 Million ≈ $131.74 Million |
-82.20% |
| 2020-12-31 | CHF585.48 Million ≈ $740.21 Million |
+256.25% |
| 2019-12-31 | CHF164.35 Million ≈ $207.78 Million |
-75.01% |
| 2018-12-31 | CHF657.62 Million ≈ $831.42 Million |
-11.07% |
| 2017-12-31 | CHF739.51 Million ≈ $934.94 Million |
+45.58% |
| 2016-12-31 | CHF507.97 Million ≈ $642.21 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Idorsia Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 318332800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CHF12.54 Million | % |
| Other Components | CHF2.37 Billion | % |
| Total Equity | CHF-1.14 Billion | 100.00% |
Idorsia Ltd Competitors by Market Cap
The table below lists competitors of Idorsia Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yindu Kitchen Equipment Co Ltd
SHG:603277
|
$1.03 Billion |
|
Corporación Interamericana de Entretenimiento S.A.B. de C.V
MX:CIEB
|
$1.03 Billion |
|
Sano Bruno's Enterprises Ltd
TA:SANO1
|
$1.03 Billion |
|
TravelSky Technology Limited
F:TVL
|
$1.03 Billion |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
|
$1.03 Billion |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
|
$1.03 Billion |
|
Coretronic
TWO:5371
|
$1.03 Billion |
|
Baltic Classifieds Group PLC
LSE:BCG
|
$1.03 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Idorsia Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,212,145,000 to -1,137,173,000, a change of 74,972,000.
- Net loss of 112,000,000 reduced equity.
- Share repurchases of 84,428,000 reduced equity.
- New share issuances of 84,428,000 increased equity.
- Other comprehensive income decreased equity by 2,859,000.
- Other factors increased equity by 189,831,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF-112.00 Million | -9.85% |
| Share Repurchases | CHF84.43 Million | -7.42% |
| Share Issuances | CHF84.43 Million | +7.42% |
| Other Comprehensive Income | CHF-2.86 Million | -0.25% |
| Other Changes | CHF189.83 Million | +16.69% |
| Total Change | CHF- | % |
Book Value vs Market Value Analysis
This analysis compares Idorsia Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CHF4.24 | CHF4.76 | x |
| 2017-12-31 | CHF6.45 | CHF4.76 | x |
| 2018-12-31 | CHF5.26 | CHF4.76 | x |
| 2019-12-31 | CHF1.30 | CHF4.76 | x |
| 2020-12-31 | CHF4.10 | CHF4.76 | x |
| 2021-12-31 | CHF0.62 | CHF4.76 | x |
| 2022-12-31 | CHF-3.73 | CHF4.76 | x |
| 2023-12-31 | CHF-5.43 | CHF4.76 | x |
| 2024-12-31 | CHF-6.64 | CHF4.76 | x |
| 2025-12-31 | CHF-5.30 | CHF4.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Idorsia Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -50.68%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-109.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -65.42% | 0.00% | 0.00x | 1.79x | CHF-386.37 Million |
| 2017 | -1.91% | -9.03% | 0.12x | 1.73x | CHF-88.81 Million |
| 2018 | -58.13% | -637.42% | 0.04x | 2.12x | CHF-452.86 Million |
| 2019 | -286.85% | -2076.70% | 0.02x | 5.82x | CHF-511.89 Million |
| 2020 | -76.03% | -620.31% | 0.05x | 2.45x | CHF-503.67 Million |
| 2021 | -608.99% | -1795.23% | 0.02x | 14.23x | CHF-645.02 Million |
| 2022 | 0.00% | -852.60% | 0.11x | 0.00x | CHF-761.80 Million |
| 2023 | 0.00% | -195.50% | 0.30x | 0.00x | CHF-201.05 Million |
| 2024 | 0.00% | -234.43% | 0.22x | 0.00x | CHF-142.54 Million |
| 2025 | 0.00% | -50.68% | 0.47x | 0.00x | CHF1.72 Million |
Industry Comparison
This section compares Idorsia Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $578,493,929
- Average return on equity (ROE) among peers: -26.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Idorsia Ltd (IDIA) | CHF-1.18 Billion | -65.42% | N/A | $1.03 Billion |
| Addex Therapeutics Ltd (ADXN) | $39.24 Million | -4.19% | 0.08x | $3.89 Million |
| Bachem Holding AG (BANB) | $1.17 Billion | 8.61% | 0.18x | $5.42 Billion |
| BB Biotech AG (BION) | $3.90 Billion | 17.72% | 0.02x | $2.93 Billion |
| Bioversys AG (BIOV) | $10.68 Million | -175.24% | 2.27x | $160.82 Million |
| Basilea Pharmaceutica AG (BSLN) | $-92.96 Million | 0.00% | 0.00x | $686.09 Million |
| MINDMAZE THERAPEUTICS HOLDING SA (MMTX) | $86.00K | -1.16% | 0.08x | $31.84 Million |
| Molecular Partners AG (MOLN) | $176.43 Million | -35.13% | 0.12x | $145.86 Million |
| Newron Pharmaceuticals SpA (NWRN) | $-11.13 Million | 0.00% | 0.00x | $243.84 Million |
| Relief Therapeutics Holding AG (RLF) | $14.30 Million | -52.18% | 0.39x | $36.33 Million |
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more